Maya Rahme
Overview
Explore the profile of Maya Rahme including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rahme M, Al-Shaar L, Tamim H, Fuleihan G
J Endocr Soc
. 2024 Nov;
8(12):bvae168.
PMID: 39534319
Context: Evidence for a beneficial role of vitamin D on blood pressure (BP) outcomes is inconclusive. Objective: This work aimed to investigate the effect of 2 doses of cholecalciferol (vitamin...
2.
Assaad M, Ajjour S, Rahme M, Al-Shaar L, Sakr M, Ghattas H, et al.
Br J Nutr
. 2024 May;
132(2):200-208.
PMID: 38818715
The Mediterranean Region registers an increasing prevalence of obesity. The region lacks a diet screener to assess obesogenic nutrients. This study aimed to evaluate the reproducibility and validity of the...
3.
Wu F, Fuleihan G, Cai G, Lamberg-Allardt C, Viljakainen H, Rahme M, et al.
Am J Clin Nutr
. 2023 Sep;
118(3):498-506.
PMID: 37661104
Background: Vitamin D supplements are widely used for improving bone health in children and adolescents, but their effects in vitamin D-deficient children are unclear. Objectives: This study aimed to examine...
4.
Bassatne A, Murad M, Piggott T, Drake M, Rahme M, Fuleihan G
J Clin Endocrinol Metab
. 2022 Dec;
108(3):563-584.
PMID: 36545699
Background: Integrating shared decision making between patients and physicians and incorporating their values and preferences in the development of clinical practice guidelines (CPGs) is of critical importance to optimize CPG...
5.
Jabbour J, Rahme M, Mahfoud Z, Fuleihan G
Endocrine
. 2022 Apr;
76(3):749-750.
PMID: 35460031
No abstract available.
6.
Jabbour J, Rahme M, Mahfoud Z, Fuleihan G
Endocrine
. 2022 Jan;
76(1):162-171.
PMID: 35028890
Background: Hypovitaminosis D is associated with Sarcopenic Obesity (SO), but evidence from randomized Vitamin D 3 (VD3) trials is scarce. Objective: Compare the effect of VD3 supplementation, at two doses,...
7.
Bassatne A, Rahme M, Piggott T, Murad M, Hneiny L, Fuleihan G
BMJ Open
. 2021 Oct;
11(10):e051141.
PMID: 34635523
Introduction: Hypercalcaemia of malignancy (HCM) is the second most common cause of hypercalcaemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with...
8.
Bacha D, Rahme M, Al-Shaar L, Baddoura R, Halaby G, Singh R, et al.
J Clin Endocrinol Metab
. 2021 May;
106(9):e3644-e3654.
PMID: 33954783
Context: Guidelines for the dosage of vitamin D supplementation vary widely globally. Objective: To investigate the impact of 2 vitamin D doses, bracketed between the IOM recommended dietary allowance (RDA)...
9.
Bassatne A, Basbous M, Chakhtoura M, El Zein O, Rahme M, Fuleihan G
Metabolism
. 2021 Mar;
119:154753.
PMID: 33774074
Background: Disease severity and mortality rates due to COVID-19 infection are greater in the elderly and chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin D plays...
10.
El Sabeh M, Ghanem P, Al-Shaar L, Rahme M, Baddoura R, Halaby G, et al.
J Clin Endocrinol Metab
. 2020 Dec;
106(2):e990-e1001.
PMID: 33280041
Context: Questions regarding the superiority of free and bioavailable 25-hydroxyvitamin D [25(OH)D] in predicting health outcomes remain unresolved. Objective: This study investigates the impact of vitamin D variables-total, bioavailable, or...